Early Stage Disease. Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center
|
|
- Adam Patrick
- 5 years ago
- Views:
Transcription
1 SABCS 2014: Early Stage Disease Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center Topics for Discussion Chemotherapy plus 10 year update of E1199: what is the best taxane dose and schedule? NSABP B36: is more anthracycline better? Chemotherapy for older women? Bevacizumab in TNBC: outcome better than expected HER2+ disease Who benefits from trastuzumab? Hormone therapy SOFT: Optimal hormone therapy for premenopausal women 1
2 E1199: Compare Taxane Type and therapy in Stage IIA-IIIA Breast Cancer 4954 women enrolled, all subtypes (TN, ER+: 69%, HER2+: 20%) ACq3weeksx4followedby: Weekly paclitaxel x 12 Q3 week paclitaxel x 4 Weekly docetaxel x 12 (35 mg/m2) Q3 week docetaxel x 3 (100 mg/m2) 90% followed for at least 10 yrs: median FU 12.1 yrs Other reports BMI > 30 mg/m2 associated with worse outcome in ER+ disease Black race associated with worse outcome in ER+ disease No association between neuropathy and clinical outcome Primary comparisons (DFS and OS) P1/P3 vs D1/D3: no difference P1/D1 vs D3/P3: no difference Sparano SABCS 2014, Cancer 2012, JNCI 2012; Schneider JCO 2012 E1199: 10 Year Update Taxane by schedule interaction tests via stratified Cox model P=0.007 for OS P<0.001 for DFS OS: D1/P3 OS: D3/P (0.88, 1.18) 0.86 (0.73, 1.00) OS: P1/P (0.75, 1.02) DFS: D1/P3 096( (0.84, 110) 1.10) DFS: D3/P (0.68, 0.90) DFS: P1/P (0.73, 0.96) Hazard ratios and 95% CI from stratified Cox models HR for P1/P3 HR for D3/P3 HR for D1/P3 95% CI for P1/P3 95% CI for D1/P3 95% CI for D3/P3 2
3 E1199: Subsets In 1025 pts with TNBC: P1 vs P3 Improved OS from 66 to 75% (HR.69) Improved DFS from 59 to 69% (HR.69) This improvement was not seen with q3 wk docetaxel In 2785 pts with HR+/HER2 neg disease: D3 vs P3 Improved DFS from 69 to 75% (HR.76); no difference in OS Strong associations with inferior outcomes observed for: Obesity (BMI > 30 kg/m2) Black race independent of obesity, and confirmed in other reports How to improve on these results? NRG-BR003 for node positive/high risk node negative TNBC AC followed by weekly paclitaxel x 12 +/- carboplatin Pan et al. J Clin Oncol 2014; 32:5s (suppl; abstr 503); Lu et al. J Clin Oncol 2011; 29: 3358 NSABP B36: Is Longer Better? Node negative breast cancer: 2,722 patients (2004-8) AC x 4 vs. FEC 100 x 6 Initially 2 x 2 study with celecoxib: closed after 327 entered Amended to allow sequential trastuzumab if HER2+ in 2005 Median FU: 7 years, FU available in 99% 35% ER negative 50% T<2 cm, 44% grade 3 11% received trastuzumab Toxicity: increased with FEC100 (LVSD 0.1%) Efficacy DFS at 8 years: 82% in both arms, no difference in OS (92%) 1.5% mortality, 4.7% distant recurrence Jacobs et al (presented by Geyer), SABCS
4 ICE: Adjuvant Ibandronate +/- Capecitabine 1358 N+/N- high risk; age > 65 Ibandronate 50 mg PO daily or 6 mg IV 4wks x 2 years +/- Capecitabine 2000mg/m 2 14 day on, 7 d off x 6 cycles Hormone therapy as indicated, no trastuzumab Median age 71; 81% HR+; 18.5% HER2+; TN 14% 76% completed ibandronate; 83% completed cape Invasive disease free survival at 5 years 78.8 vs 75% (HR 1.04) No difference in any subgroup OS at 5 years: 90 vs 88% 25% had bone related events (not mets) Hormone therapy is a good thing in older women with HR+ early stage higher risk breast cancer Role of chemotherapy? CALGB 49907, Muss et al, NEJM 2009) von Minckwitz et al, SABCS 2014 BEATRICE: Median FU 56 mo women with TNBC, early stage Randomized to chemo with or witthout bevacizumab Outcome at 5 years OS: 88% DFS: ~78.5% No benefit from bevacizumab Chemotherapy is highly effective in early stage TNBC Bell et al, SABCS
5 HER2+ Disease: NSABP B-31 Subset B-31 (N=1578) 5% 6% 14% 28% 47% Basal-like HER2- enriched Luminal A Luminal B Normal-like HER2 negative (n=146) 3% 22% 23% 5% 47% ER negative (N=737) N=1578 ER positive (N=841) 2% 1% 6% 2% 8% 13% 25% 26% 71% 46% Pogue-Geile et al (presented by Paik), SABCS 2014; Pogue-Geile et al, JCO 2015 PAM50 RORP and RORS 5
6 N=672 8 PIK3CA hot spot mutations: Frequency in B31 = 24.7% Unlike neoadjuvant and metastatic data: no prognostic impact Association between Intrinsic Subtypes and HER2, ER, and 8-gene Predictive Signature 8-gene predictive model validation set (Pogue-Geile et al, JNCI 2013) In multivariate analysis: 8-gene ACT ACTH predictive model group 2 (n=449) was the only ACTH ACT HR 0.60( ) significant predictive P=0.011 marker P<.0001 of trastuzumab benefit group 1 (n=100) HR 1.58 ( ) P=0.29 Interaction p= (ESR1, CA12, GATA3, IGFR1, NAT1, ERBB2, GRB7, C17orf37) ACTH group 3 (n=442) HR 0.28( ) ACT Pogue-Geile et al, JNCI
7 Summary PAM50 intrinsic subtype or PIK3CA mutation did not identify subgroups without benefit from trastuzumab NSABP B47 is investigating the activity of trastuzumab in HER2 negative early stage BC Differential benefit in micrometastatic disease? Cancer stem cells from HER2 negative breast cancer cells are inhibited by trastuzumab Advanced or Neoadjuvant setting Adjuvant setting Trastuzumab started t at the time of tumor cell injection inhibit tumor growth of HER2 negative BC cells Ithimakin et al, Cancer Res 2013 This article was published on December 11,2014, at NEJM.org. 7
8 What are the Questions? For premenopausal women with hormone responsive early stage breast cancer, how much is enough? Should all/any women have their ovaries suppressed? SOFT If OS, tamoxifen or an AI? SOFT and TEXT combined analysis In whom can we avoid chemotherapy? No randomized trial Inferential data from SOFT/TEXT and ABCSG12 Is the bang worth the buck? Toxicity in SOFT How long should hormone therapy be given? What is the role of adjuvant bisphosphonates? Breast Cancer in Premenopausal Women Most frequent cancer diagnosis in women worldwide Most common cause of cancer death Age at diagnosis in the US (estimates for 2013) 21% in women < age 50 (~49,000) 4.7% in women < age 40 (~11,000) Hormone receptor positive still the most common subtype Incidence, particularly in younger women, has increased in the last decade 8
9 Outcome at 15 years with Tamoxifen ER+ disease, entry age < 45 years, 79% chemotherapy (n-2614) EBCTCG, Lancet 2011 Disease-Free Survival for Women Under 40 Years: E5188 INT 0101 (n=436/1500, all N+) Probability yr DFS Age % 02 CAF 48% < 35 10% 0.2 CAFZ 55% % CAFZT 64% >39 71% Disease-Free Survival (Years) Davidson et al. J Clin Oncol,
10 Meta-Analysis of LHRH Agonists as Adjuvant Therapy for Premenopausal Women with HR+ Breast Cancer 9,022 women with HR+ disease; 6.8 years med FU Tamoxifen +/- LHRH agonist No significant decrease in risk of recurrence (HR.85) or death after recurrence (HR 0.84) Chemotherapy +/- tamoxifen: addition of LHRH agonist provides modest benefit Reduction in risk of recurrence of 12.2% (HR.88) Reduction in risk of death after recurrence of 15.1% 1% (HR.85) As effective as chemotherapy regimens used in these trials (no taxanes, mostly non-anthracycline) Suboptimal use of tamoxifen Cuzick, et al; LHRH Metaanlysis Group. Lancet. 2007;369:1714 Meta-analysis of LHRH agonists as adjuvant treatment in premenopausal patients with ER + breast cancer: Recurrence risk by age 35 years HR years HR years HR years HR years HR 0.85 N=9022 Significant interaction for recurrence of age for addition of LHRH agonist to chemotherapy with or without tamoxifen (p=0.046) Lancet. 2007;369:
11 NSABP B30: Impact of Type of Chemotherapy and Age on Amenorrhea and Outcome <40 > 40 NSABP B30 substudy (Swain et al, NEJM 2010) 1885 women, N+, receiving chemotherapy In women with ER+ disease: Amenorrhea for > 6 months predicted improved OS (HR 0.52, P=0.002) and DFS (0.51, P<0.001) Ganz P et al. J Clin Oncol 2011; Swain et al. NEJM 2010 Patient/tumor characteristics 23% < 40 yrs of age 76% T1, 30% node +, 20% grade 3 95% of women are alive at 7.9 years median FU Worse survival with AI Inadequate OFS? Role of zoledronate? At 8 years, numerical advantage but loss of significance for DFS & OS Gnant et al, Ann Oncol
12 Pfeiler et al, JCO 2011 TEXT and SOFT Designs Enrolled 11/03-1/11 Premenopausal < 12 weeks after surgery Planned OFS No planned chemo OR planned chemo Premenopausal < 12 weeks after surgery No chemo OR Remain premenopausal < 8 mos after chemo R A N D O M I Z E R A N D O M I Z E TEXT: 2672 Tamoxifen+OFS x 5 yr Exemestane+OFS x 5 yr SOFT: 3047 Tamoxifen x 5 yrs (1018) Tamoxifen+OFS x 5 yr (1015) Exemestane+OFS x 5 yr (1014) Joint Analysis N=4690 Median FU 5.7 years SOFT Primary Analysis N=2033 Median FU years Pagani et al, ASCO NEJM 2014, Francis et al, SABCS NEJM
13 Definition of Endpoints, Statistics Primary DFS Invasive recurrence, invasive i contralateral t l cancer, second malignancy, death without prior cancer event Secondary BCFI Invasive recurrence or contralateral breast cancerr DRFI Distant recurrence free interval OS Stratification factors: chemo (+/-), node status (+/-) Protocol amendment 2011 (before efficacy data) Primary analysis T/OFS vs T Secondary analysis E/OFS vs T Patient Characteristics SOFT TEXT No Chemo Chemo No chemo Chemo 47% (949) 53% (1084) 40% 60% Median age LN+ 9% 57% 21% 66% T > 2 cm 14% 47% 19% 53% Grade 1 41% 14% 26% 12% Grade 3 7% 35% 12% 37% HER2+ve 4% 18% 5% 17% SOFT unique design Those who received chemotherapy had to recover ovarian function by 8 months (measured by serum estradiol) to be eligible Tamoxifen allowed during that time In women < 35 years, 94% received chemotherapy 13
14 Primary Analysis: Disease-free Survival 5.6 years median follow-up Primary analysis in overall population not significant (p=0.10) Multivariable Cox model HR=0.78 (95% CI ) p=0.03 Secondary Objectives E + OFS vs T alone: 4.3% absolute improvement (HR.68) E + OFS vs T alone: 4.5% absolute improvement (HR.64) T+OFS v T: 19% relative reduction in BC recurrence, p=0.09 E+OFS v T: 36% relative reduction in BC recurrence, 5y BCFI >90% 14
15 Premenopausal: No Chemotherapy Cohort selected for low risk clinicopathologic features 90% age 40yr, 91% node negative, 85% tumor 2cm, 41% grade 1 DFS: Summary: Overall Population No additional benefit adding OFS to T in the entire population E + OFS vs T alone: 4.3% absolute improvement (HR.68) Breast Cancer-Free Interval (BCFI): No significant improvement adding OFS to T E + OFS vs T alone: 4.5% absolute improvement (HR.64) Patients not receiving adjuvant chemotherapy (949): Physicians were able to select patients with excellent outcome regardless of endocrine therapy at 5.6 yrs 1% mortality (10/949) 1.4% DRFI (13/949) Older, node negative, T1 tumors, almost half grade 1 15
16 Premenopausal: After Prior Chemotherapy T+OFS v T: Absolute improvement in 5-yr BCFI of 4.5% E+OFS v T: Absolute improvement in 5-yr BCFI of 7.7% and 5-yr DRFI of 4.2% All women < 35 years of age 350 patients (11.5%) under age 35 94% received chemotherapy in this age group 16
17 Results: Biology and Risk Drive Benefit of Ovarian Suppression BCFI in premenopausal women who retain ovarian production of estrogen following adjuvant chemotherapy T + OFS > T E + OFS >> T This difference is even greater in women < 35 yrs of age Endpoint Premenopausal after chemo BCFI in < 35 yo (94% received chemo) Absolute improvement at 5 years HR (95% CI) T + OFS v. T E + OFS v. T BCFI 45% 4.5% 77% 7.7% 0.78 ( ) 0.65 ( ) DRFI 1.2% 0.87 (, ) 4.2% 0.72 ( ) 11.2% 15.7% DRFI: distant recurrence free interval BCFI: breast cancer free interval; Endpoint All patients combined TEXT + SOFT Joint Analysis BCFI DRFI Absolute improvement at 5 years E + OFS vs T + OFS 4% 1.8% No chemotherapy (TEXT only) Premenopausal after/with chemo BCFI 3% (HR 0.41) TEXT vs SOFT BCFI 5.5 vs 3.9% DRFI 2.6 vs 3.4% TEXT, no chemotherapy: 21% node positive, 16% < 40, 19% T > 2 cm DRFI: distant recurrence free interval BCFI: breast cancer free interval; Pagani et al, NEJM
18 Cost of Treatment: Toxicity 15% stopped OFS by 2 years, 22% by 3 years. Provider reported, clinically important Depression reported in ~ 50%, 4% severe, 5% increase with OFS Increase in menopausal symptoms, osteoporosis, insomnia most marked Patient reported (85% of trial population) No difference in global QOL with use of OFS in primary analysis despite differences in endocrine symptoms Global QOL indicators do not reflect important endocrine effects Endocrine differences are less pronounced after 2 years Compliance or adjustment to menopause? Endocrine toxicity overall less in women with prior chemotherapy Ribi et al, SABCS 2014 Selected Adverse Events T+OFS (N=1005) T (N=1006) CTCAE v3.0 Grade 1-4 Grade 3-4 Grade 1-4 Grade 3-4 Hot flushes/flashes 93% 13% 80% 8% Sweating 62% -- 48% -- Libido decrease 47% -- 42% -- Vaginal dryness 50% -- 42% -- Depression 52% 4% 47% 4% Insomnia 57% 5% 46% 3% Musculoskeletal 75% 5% 69% 6% symptoms Osteoporosis 20% (6%) 0.3% 12% (3%) 0.1% (% T< -2.5) Hypertension 23% 7% 17% 5% Glucose intolerance 3% 1% 2% 0.3% (diabetes)* Hyperglycemia* 5% 1% 2% 0.1% Any Gr 3-4 targeted AE -- 31% -- 24% *Added during trial conduct, may be under-reported 18
19 Treatment Effect: by Cohort Changes from baseline to month 6 for selected indicators Ribi et al, SABCS 2014 Treatment Effect: Global QoL E+OFS 19
20 Take Home Points and Additional Thoughts Successful international collaboration Accrual period 8 years Rigorous definition of menopausal status Clear and stringent definition of hormone receptor positive disease >10% by IHC Long follow-up planned; tissue analyses offer great potential Excellent and careful assessment of patient reported outcomes Its still early! Short follow-up for distant recurrence and overall survival Attention needs to be paid to management of toxicity Endocrine symptoms Depression Hypertension Bone health Sexual dysfunction Risk vs benefit requires individualization Role of genomic tests in decision making for intermediate risk patients? 2014: New Algorithm for Premenopausal Hormone Receptor Positive Disease? No chemotherapy Premenopausal Hormone receptor positive early stage breast cancer Chemotherapy Low risk Smaller tumors Node negative Grade 1 Older Intermediate risk Low grade but larger tumor Low grade but node positive High risk Larger tumors Node positive Grade 3 Younger T x at least 5 years Duration? Chemo + OS/T or E? OS + endocrine rx? OS + T or E > T (particularly in < 35 yo) OS + E > OS + T 20
Adjuvant endocrine therapy (essentials in ER positive early breast cancer)
Adjuvant endocrine therapy (essentials in ER positive early breast cancer) Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental Therapeutics Outline Picking optimal adjuvant endocrine
More informationLong Term Toxicity of Endocrine Therapy for premenopausal women with ER positive breast cancer
Global Breast Cancer Conference 2017 21 st Apr, 2017@Chezu Island Long Term Toxicity of Endocrine Therapy for premenopausal women with ER positive breast cancer Shinji Ohno, M.D., Ph.D., F.A.C.S. Breast
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationSOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer
SOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer Charles Moertel Lecture May 12, 2017 Gini Fleming Charles Moertel Founder of NCCTG Dedication to high quality clinical
More information38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI %
38 years old, premenopausal, had L+snbx Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI67 5-10% Question: What will you do now? 1. Give adjuvant chemotherapy 2. Send for Oncotype
More informationShould premenopausal HR+ve breast cancer receive LHRH?
Should premenopausal HR+ve breast cancer receive LHRH? Hesham Elghazaly, MD Prof. Clinical Oncology, Ain Shams University President of the BGICS Should premenopausal HR+ve breast cancer receive LHRH? NO?
More informationOPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER
OPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER STEPHEN E. JONES, M.D. US ONCOLOGY RESEARCH THE WOODLANDS, TX TOPICS PREMENOPAUSAL BREAST CANCER POSTMENOPAUSAL BREAST CANCER THE FUTURE TOPICS PREMENOPAUSAL
More informationGene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA
Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA When Are Biomarkers Ready To Use? Same Rules for Gene Expression Panels Key elements
More informationExtended Hormonal Therapy
Extended Hormonal Therapy Dr. Caroline Lohrisch, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Optimal Endocrine Therapy for Women with Hormone Receptor Positive Early
More informationUpdates From San Antonio Breast Cancer Symposium 2017
Updates From San Antonio Breast Cancer Symposium 2017 Rob Coleman University of Sheffield Presentation Outline New Insights into adjuvant endocrine treatment Duration of treatment Perioperative therapy
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationSan Antonio Breast Cancer Symposium 2013
15 th Annual Advances in Oncology Navigating Breast Cancer Therapeutics: Early and Late Stage Disease Scott Christensen, MD Professor, Hematology/Oncology UC Davis Comprehensive Cancer Center 15th Annual
More informationUse of Ovarian Suppression and Ablation in Breast Cancer Treatment
Use of Ovarian Suppression and Ablation in Breast Cancer Treatment Dr Marina Parton Consultant Medical Oncologist Royal Marsden and Kingston Hospitals Overview Breast cancer phenotypes Use of ovarian manipulation
More informationEndocrine Therapy in Premenopausal Breast Cancer. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology
Endocrine Therapy in Premenopausal Breast Cancer Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology Ovarian Ablation or Suppression vs. Not in ER + or ER UK Breast Cancer
More informationDisclosures. ASCO Highlights Breast Cancer. Associa4on of Northern California Oncologists 8/25/14
ASCO Highlights 2014 Associa4on of Northern California Oncologists Breast Cancer Sco+ Christensen, MD Professor, Hematology/Oncology UC Davis Comprehensive Cancer Center Disclosures 1 Outline Novel TherapeuFcs/Early
More informationNon-Anthracycline Adjuvant Therapy: When to Use?
Northwestern University Feinberg School of Medicine Non-Anthracycline Adjuvant Therapy: When to Use? William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More informationLuminal early breast cancer: (neo-) adjuvant endocrine therapy
CAMPUS GROSSHADERN CAMPUS INNENSTADT KLINIK UND POLIKLINIK FÜR FRAUENHEILKUNDE UND GEBURTSHILFE DIREKTOR: PROF. DR. MED. SVEN MAHNER Luminal early breast cancer: (neo-) adjuvant endocrine therapy Nadia
More informationEARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino
EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY Dr. Carlos Garbino EARLY BREAST CANCER ADJUVANT CHEMOTHERAPY SUSTANTIVE DIFFICULTIES FOR A WORLDWIDE APPLICABILITY DUE TO IMPORTANT INEQUALITIES + IN DIFFERENT
More informationAdjuvant chemotherapy in older breast cancer patients: how to decide?
Adjuvant chemotherapy in older breast cancer patients: how to decide? H. Wildiers University Hospitals Leuven Belgium Wildiers H, Kunkler I, Lancet Oncol 2007 Biganzoli L, Wildiers H, Lancet Oncol. 2012
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Dilemmas in Adjuvant Chemotherapy Is adjuvant chemotherapy effective in ER+
More informationORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA
ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA THE NATURAL HISTORY OF HORMONE RECEPTOR- POSITIVE BREAST CANCER IS VERY LONG Recurrence hazard rate 0.3 0.2 0.1 0 ER+ (n=2,257)
More informationRadiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
More informationTerapia Hormonal da Paciente Premenopausa
I Congresso de Oncologia D Or 5 e 6 de julho de 2013 Terapia Hormonal da Paciente Premenopausa Antonio C. Wolff, MD, FACP, FASCO Professor de Oncologia Programa de Câncer de Mama Johns Hopkins University
More informationBiomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationMEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014
MEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014 Dr Thomas Yau Clinical Assistant Professor MBBS(HK), MRCP (UK), FHKCP (Med Onc), FHKAM( Medicine), FRCP(London) Queen Mary Hospital The University of Hong Kong
More informationNeoadjuvantTreatment In BC When, How, Who?
NeoadjuvantTreatment In BC When, How, Who? Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service, MSKCC Professor of Medicine, Weill Cornell Medical College President, ASCO 15 Potential Benefits Of
More informationEmerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer
Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationASCO and San Antonio Updates
ASCO and San Antonio Updates 30 th Annual Miami Breast Cancer Conference March 7-10, 2013 Debu Tripathy, MD Professor of Medicine University of Southern California Norris Comprehensive Cancer Center Breakthroughs
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2013 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley
More informationAdjuvant Endocrine Therapy: How Long is Long Enough?
Adjuvant Endocrine Therapy: How Long is Long Enough? Harold J. Burstein, MD, PhD Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts hburstein@partners.org I have no conflicts to
More informationThe Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now?
1 The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now? Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program
More information8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview
Overview PONDERing the Need to TAILOR Adjuvant in ER+ Node Positive Breast Cancer Jennifer K. Litton, M.D. Assistant Professor The University of Texas M. D. Anderson Cancer Center Using multigene assay
More informationPoint of View on Early Triple Negative
Point of View on Early Triple Negative Valentina Rossi, MD UOSD Oncologia dei Tumori della Mammella Azienda Ospedaliera S.Camillo-Forlanini VRossi@scamilloforlanini.rm.it Outline Neoadjuvant Setting IPSY-2
More informationOPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER. Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx
OPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx ANTHRACYCLINES AND TAXANES ARE COMMONLY USED USED IN MOST REGIMENS
More information非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和
資料 2 2 非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和 1 Preclinical studies Therapeutic Window: Efficacy/Toxicity Disease Specificity Subtype Specificity Combination: Concurrent/Sequential Therapeutic situation: Response/
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationRole of Primary Resection for Patients with Oligometastatic Disease
GBCC 2018, April 6, Songdo ConvensiA, Incheon, Korea Panel Discussion 4, How Can We Better Treat Patients with Metastatic Disease? Role of Primary Resection for Patients with Oligometastatic Disease Tadahiko
More informationESMO Breast Cancer Preceptorship Singapore November Special Issues in Treatment of Young Women with Breast Cancer
ESMO Breast Cancer Preceptorship Singapore November 2017 Special Issues in Treatment of Young Women with Breast Cancer Prudence Francis MD Peter MacCallum Cancer Centre Melbourne, Australia Conflict of
More informationAssessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint
Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint William J. Gradishar, MD Professor of Medicine Robert H. Lurie Comprehensive Cancer Center of Northwestern University Classical
More informationBreast cancer treatment
Report from the San Antonio Breast Cancer Symposium Breast cancer treatment Determining the best options for select patient groups Sara Soldera, MD, Resident; Nathaniel Bouganim, MD, FRCPC, Medical Oncologist;
More informationHormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension?
Hormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension? Ivana Sestak, PhD Centre for Cancer Prevention Wolfson Institute of Preventive Medicine Queen Mary University London
More informationAny News in EBC? Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute November 11, 2016
Any News in EBC? Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute November 11, 2016 Yes! Age disparities vary by tumor subtype Genomic risk prediction data in young women Adjuvant systemic therapy
More informationNSABP Pivotal Breast Cancer Clinical Trials: Historical Perspective, Recent Results and Future Directions
1 1 NSABP Pivotal Breast Cancer Clinical Trials: Historical Perspective, Recent Results and Future Directions Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health
More informationStudy Of Letrozole Extension. Coordinating Group IBCSG IBCSG BIG 1-07
tudy Of Letrozole Extension Coordinating Group IBCSG IBCSG 35-07 BIG 1-07 A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant
More informationMechanisms of Resistance to. Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
Mechanisms of Resistance to Hormonal Therapy Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Antagonizing Estrogen Dependent Growth Premenopausal
More informationOVERVIEW OF GENE EXPRESSION-BASED TESTS IN EARLY BREAST CANCER
OVERVIEW OF GENE EXPRESSION-BASED TESTS IN EARLY BREAST CANCER Aleix Prat, MD PhD Medical Oncology Department Hospital Clínic of Barcelona University of Barcelona esmo.org Disclosures Advisory role for
More informationLocally Advanced Breast Cancer: Systemic and Local Therapy
Locally Advanced Breast Cancer: Systemic and Local Therapy Joseph A. Sparano, MD Professor of Medicine & Women s Health Albert Einstein College of Medicine Associate Chairman, Department of Oncology Montefiore
More informationPostoperative Adjuvant Chemotherapies. Stefan Aebi Luzerner Kantonsspital
Postoperative Adjuvant Chemotherapies Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Does Chemotherapy Work in Older Patients? ER : Chemotherapy vs nil Age
More informationSystemic Therapy for Locally Advanced Breast Cancer
Systemic Therapy for Locally Advanced Breast Cancer Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology National University Cancer Institute, Singapore Clinical Care Senior Principal
More information2014 San Antonio Breast Cancer Symposium Review
2014 San Antonio Breast Cancer Symposium Review HER2 Positive Disease 01-10-2015 Elisavet Paplomata, MD Assistant Professor Hematology & Medical Oncology Emory University Winship Cancer Institute S6-01
More informationTNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017
TNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017 The problem with TNBC 1. Generally more aggressive 2. ONLY chemotherapy 3. No other
More informationThe TAILORx Trial: A review of the data and implications for practice
The TAILORx Trial: A review of the data and implications for practice Angela DeMichele, MD, MSCE Jill & Alan Miller Endowed Chair in Breast Cancer Excellence Professor of Medicine and Epidemiology University
More informationSeigo Nakamura,M.D.,Ph.D.
Seigo Nakamura,M.D.,Ph.D. Professor of Surgery Director of Breast Center Showa University Hospital Chairman of the board of directors Japan Breast Cancer Society Inhibition of Estrogen-Dependent Growth
More informationTAILORx: Established and Potential Implications for Clinical Practice
TAILORx: Established and Potential Implications for Clinical Practice Joseph A. Sparano, MD Study Chair, TAILORx Vice-Chair, ECOG-ACRIN Cancer Research Group Hello Healthcare Summit Berlin, Germany March
More informationSYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER
SYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER Sunil Shrestha 1*, Ji Yuan Yang, Li Shuang and Deepika Dhakal Clinical School of Medicine, Yangtze University, Jingzhou, Hubei Province, PR. China Department
More informationThe Three Ages of Systemic Adjuvant Therapy for EBC
The Three Ages of Systemic Adjuvant Therapy for EBC 1896-2018 Nicholas Wilcken Westmead Hospital Petersham Institute University of Sydney Questions to be answered (concentrating on chemotherapy) Why should
More informationThe Role of Angiogenesis Inhibition in Breast Cancer Today: Lessons Learned
The Role of Angiogenesis Inhibition in Breast Cancer Today: Lessons Learned Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education UCSF Helen Diller Family Comprehensive
More informationNovel Preoperative Therapies for HER2-Positive Breast Cancer. Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center
Novel Preoperative Therapies for HER2-Positive Breast Cancer Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center Key Findings to Date in the Neoadjuvant Therapy of HER2+
More informationSystemic therapy: HER-2 update. Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven
Systemic therapy: HER-2 update Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven New drugs Strategic issues Specific anti-her2 drugs Lapa$nib /Nera$nib Baselga & Swain,
More informationChoosing between different hormonal therapies. Rudy Van den Broecke UZ Ghent
Choosing between different hormonal therapies Rudy Van den Broecke UZ Ghent What is the golden standard in premenopausal hormonal sensitive early breast cancer? Ovarian Suppression alone 5 years Tamoxifen
More informationBREAST CANCER RISK REDUCTION (PREVENTION)
BREAST CANCER RISK REDUCTION (PREVENTION) Articles Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled
More informationAdjuvant bisphosphonates: our recommendations
Adjuvant bisphosphonates: our recommendations Andreas Makris Mount Vernon Cancer Centre OPTIMA launch meeting, 27 April 2017 Breast Cancer Metastasis Tumour cell colonisation of bone Tumour cell proliferation
More informationAdjuvant Endocrine Therapy in Pre- and Postmenopausal Patients
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Endocrine Therapy in Pre- and Postmenopausal Patients Adjuvant Endocrine Therapy in Pre- and Postmenopausal Patients
More informationTriple negative breast cancer -neoadjuvant and adjuvant systemic therapy
Triple negative breast cancer -neoadjuvant and adjuvant systemic therapy Sung-Bae Kim, MD, PhD Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul, Korea DISCLOSURE
More informationShe counts on your breast cancer expertise at the most vulnerable time of her life.
HOME She counts on your breast cancer expertise at the most vulnerable time of her life. Empowering the right treatment choice for better patient outcomes. The comprehensive genomic assay experts trust.
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2017 Relative Risk HER2-positive Breast
More informationReview of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory
More informationBreast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
More informationHER2-Targeted Rx. An Historical Perspective
HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line
More informationAdvances in the Diagnosis and Treatment of Breast Cancer. Carol Tweed, M.D. Anne Arundel Medical Center DeCesaris Cancer Institute Annapolis, MD
Advances in the Diagnosis and Treatment of Breast Cancer Carol Tweed, M.D. Anne Arundel Medical Center DeCesaris Cancer Institute Annapolis, MD Disclosures Genomic Health: Speaker and Consultant AstraZeneca:
More informationIs Gene Expression Profiling the Best Method for Selecting Systemic Therapy in EBC? Norman Wolmark Miami March 8, 2013
Is Gene Expression Profiling the Best Method for Selecting Systemic Therapy in EBC? Norman Wolmark Miami March 8, 2013 Changing Phases claudin low Lum A Lum B Basal Her2 NIH Consensus Development Panel,
More informationRole of Genomic Profiling in (Minimally) Node Positive Breast Cancer
Role of Genomic Profiling in (Minimally) Node Positive Breast Cancer Kathy S. Albain, MD, FACP Professor of Medicine Dean s Scholar Loyola University Chicago Stritch School of Medicine Cardinal Bernardin
More informationAnthracyclines in the elderly breast cancer patients
Anthracyclines in the elderly breast cancer patients Etienne GC Brain, MD PhD Medical Oncology Centre René Huguenin, Saint-Cloud & Group GERICO, FNCLCC, Paris Centre René Huguenin - Saint-Cloud Facts about
More information(Neo-) adjuvant endocrine therapy
(Neo-) adjuvant endocrine therapy F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESO Breast Cancer Program Coordinator ESMO Board of Directors & Chair NR Committee
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationENFERMEDAD AVANZADA Qué hacemos con el triple negativo? Nuevas aproximaciones
ENFERMEDAD AVANZADA Qué hacemos con el triple negativo? Nuevas aproximaciones Javier Cortes, Hospital Universitario Ramon y Cajal, Madrid Vall d Hebron Institute of Oncology (VHIO), Barcelona Triple Negative
More informationAdjuvant Endocrine Therapy in Premenopausal Patients
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Endocrine Therapy in Premenopausal Patients Adjuvant Endocrine Therapy in Premenopausal Patients Version 2002: Scharl
More informationExtended Adjuvant Endocrine Therapy
Extended Adjuvant Endocrine Therapy After all, 5 years Tamoxifen works.. For women with ER+ primary breast cancer, previous studies have shown that treatment with tamoxifen for 5 years has a carry-over
More informationClinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and
More informationBreast : ASCO Abstracts for Review
Breast : ASCO 2011 Susana Campos, MD, MPH Dana Farber Cancer Institute Abstracts for Review Prevention Neoadjuvant Metastatic Brain mets LBA 504: Exemestane for primary prevention of breast cancer in postmenopausal
More informationWhen is Chemotherapy indicated in Advanced Luminal Breast Cancer?
When is Chemotherapy indicated in Advanced Luminal Breast Cancer? Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology Clinical Care National University Cancer Institute, Singapore
More informationSt. Gallen ASCO Carlos H. Barrios, MD
St. Gallen ASCO 2013 Carlos H. Barrios, MD PUCRS School of Medicine LACOG, LA Cooperative Group Instituto do Câncer, Hospital Mãe de Deus Porto Alegre, Brazil %Disease Free Survival 100% 50% Breast Cancer
More informationNovel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX
Novel Chemotherapy Agents for Metastatic Breast Cancer Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX New Chemotherapy Agents in Breast Cancer New classes of drugs Epothilones Halichondrin
More information03/14/2019. GnRH Analogs for Fertility Preservation: What are the Data? Educational Objectives. Outline
GnRH Analogs for Fertility Preservation: What are the Data? AHN-JH SKCCC Current Topics in Breast Cancer Symposium Karen Lisa Smith MD MPH Assistant Professor Johns Hopkins Breast and Cancer Program March
More informationA case of a BRCA2-mutated ER+/HER2 breast cancer during pregnancy
ESMO Preceptorship Programme Breast Cancer Lisbon 16,17 September 2016 Emanuela Risi Sandro Pitigliani Medical Oncology Department Hospital of Prato, Istituto Toscano Tumori, Prato, Italy A case of a BRCA2-mutated
More information4, :00 PM 9:00 PM
Consensus or Controversy? Clinical Investigators Provide Their Perspectives on Practical Issues and Research Questions in the Management of Breast Cancer Robert W Carlson, MD John Crown, MD Charles E Geyer
More informationASCO 2018 Breast Cancer updates. June 29 th 2018 Einav Gal-Yam Sheba MC
ASCO 2018 Breast Cancer updates June 29 th 2018 Einav Gal-Yam Sheba MC Early BC Adjuvant Chemotherapy benefit in HR-pos Nneg BC TAILORX Slide 1 Presented By Joseph Sparano at 2018 ASCO Annual Meeting TAILORx
More informationBreast Cancer: Chemotherapy and Novel Agents
North Carolina Oncology Association & South Carolina Oncology Society Joint Membership Meeting ~ February 26 27, 2010 The Ballantyne Resort ~ Charlotte, NC Breast Cancer: Chemotherapy and Novel Agents
More informationOptimal Treatment of Hormone Receptor Positive Disease
San Francisco, CA United States January 27, 2018 San Francisco, CA USA January 27, 2018 Optimal Treatment of Hormone Receptor Positive Disease JO CHIEN, MD Associate Professor of Medicine UCSF School of
More informationКой има полза от адювантна ендокринна терапия при карцином на гърда с какво и колко дълго?
Кой има полза от адювантна ендокринна терапия при карцином на гърда с какво и колко дълго? д-р Красимир Койнов МБАЛ Сердика, София Декларация Консултации и хонорари: Roche, Boerhinger Ingelheim, Astra
More information